During the past decade, Cedars-Sinai Heart Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 6 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cedars-Sinai Heart Institute" #1 sponsor was "Cedars-Sinai Medical Center" with 3 trials, followed by "Mezzion Pharma Co. Ltd" with 2 trials sponsored, "MyoKardia, Inc." with 2 trials sponsored, "University of Alberta" with 2 trials sponsored and "AtriCure, Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cedars-Sinai Heart Institute" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Alexion" with 1 trials as a collaborator, "Chiltern International Inc." with 1 trials as a collaborator, "Natera, Inc." with 1 trials as a collaborator and "One Lambda" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Cedars-Sinai Heart Institute" are "Atrial Fibrillation" (2 trials), "Becker Muscular Dystrophy" (2 trials), "Antibody-mediated Rejection" (1 trials), "Aortic Stenosis" (1 trials) and "Cardiac Allograft Vasculopathy" (1 trials). Many other conditions were trialed in "Cedars-Sinai Heart Institute" in a lesser frequency.

Most popular intervention types in "Cedars-Sinai Heart Institute" are "Drug" (10 trials), "Device" (3 trials), "Dietary Supplement" (2 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Udenafil" (2 trials), "mavacamten" (2 trials), "ACE-I (lisinopril) or ARB (losartan)" (1 trials) and "ACURATE Prime™ Transfemoral TAVR System XL" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cedars-Sinai Heart Institute" are 16 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Cedars-Sinai Heart Institute". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Cedars-Sinai Heart Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Cedars-Sinai Heart Institute, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".